Kenvue Inc. KVUE · NYSE
$18.90 +1.23% (+$0.23)
Summary
63 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 11 USD is left as net profit.
- It has been profitable 5 years in a row.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 11% a year over the last 3 years.
- It pays out more in dividends than it earns: 121% of profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 21.6 USD for 1 USD of yearly profit. Over the last five years it was 29.2 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 0.9% a year over 5 years. Over the last 3 years it grew by 0.4% a year. For the next fiscal year analysts expect revenue to fall by 0.5%. Earnings per share fell by 11% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 42 USD
- Research and development 0.5 USD
- Sales and administration 38 USD
- Taxes and other 8.8 USD
- Net profit 11 USD
Net profit, industry median (Household & Personal Products) 9.0 USD
Out of every 100 USD of revenue, 11 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 4.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 5.59%
- Paid out of profit
- 121%
- Raised in a row
- 2 years
You receive $1.04 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 4
- Hold 10
- Sell 0
Today's price within the analysts' price targets
The average target of $19.5 is 3.2% above today's price. 29% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Self Care 42%
- Essential Health 31%
- Skin Health and Beauty 27%
By region
- North America 48%
- EMEA 25%
- Asia Pacific 18%
- Latin America 9.1%
Self Care brings in 42% of revenue. Essential Health grew fastest, by 0.2% a year.
Segments in detail